



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore- 452 015. Fax : 0731-2723017
Tel. : 0731 - 2723016, 4066516 Email : biofilchemicals@yahoo.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-4011700, 2420926, 2424003, 2423435 Fax : 4011740

To,
The Secretary
National Stock Exchange Limited
Mumbai

CIN L24233MP1985PLC002709

Dated: 30th May, 2014

To,
The Secretary
Bombay stock Exchange Limited
P.J. Tower
Dalal street
Mumbai

Sub: Clause 41 of listing agreement for Quarterly as well as annual financial statement for year ended 31st March, 2014.

Dear Sir,

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, the Board of the directors have taken on record and approved the Audited Financial statement of the Company for the quarter as well as year ended on 31st March, 2014.

Copy of Results along with Statement of assets and liabilities and report are enclosed with letter for your information and records

This is for your information and record.

Thanking you,

Yours Faithfully

For Biofil Chemicals and pharmaceuticals Limited

Ramesh Shah
Managing Director

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED March 31, 2014

PART I		(Rs in Lakhs)				
	Particulars	For the Quarter ended March 31, 2014	For the Quarter ended December 31, 2013	For the Quarter ended March 31, 2013	Audited For The Year Ended March 31, 2014	Audited For The Year Ended March 31, 2013
	(Refer Notes Below)	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	Income from operations					
	(a) Net sales/ income from operations (Net of Excise duty)	113.24	196.76	177.27	488.88	439.65
	(b) Other operating income	112.72	115.56	152.19	228.28	161.43
	Total income from operations (net)	225.97	312.32	329.47	717.17	601.09
2	Expenses					
	(a) Cost of materials consumed	13.88	26.64	73.94	153.78	159.30
	(b) Purchases of stock-in-trade	106.21	157.31	96.54	308.10	240.97
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	(9.55)	-2.22	(8.37)	18.17	(24.73)
	(d) Employee benefits expense	24.62	4.36	34.12	41.30	43.39
	(e) Depreciation and amortisation expense	6.46	5.27	6.80	22.23	21.10
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	10.85	77.36	62.41	99.14	81.08
	Total expenses	152.48	268.72	265.44	642.73	521.11
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	73.49	43.59	64.03	74.44	79.98
4	Other income	2.83	1.05	3.05	5.98	6.20
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	76.32	44.64	67.07	80.42	86.17
6	Finance costs	4.11	3.75	12.11	15.36	19.16
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	72.21	40.89	54.96	65.06	67.01
8	Exceptional items	1.00			1.00	
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	71.21	40.89	54.96	64.06	67.01
10	Tax expense	12.40			12.40	12.77
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	58.81	40.89	54.96	51.66	54.24
12	Minority interest *					
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13±14± 15)	58.81	40.89	54.96	51.66	54.24
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10
15	Reserve excluding Revaluation Reserves				-1220.02	-1274.37
16.i	Earnings per share (before extraordinary items)					
	(of Rs. 10/- each) (not annualised):					
	(a) Basic	0.361	0.0251	0.338	0.317	0.333
	(b) Diluted					
16.ii	Earnings per share (after extraordinary items)					
	(of Rs. 10/- each) (not annualised):					
	(a) Basic	0.361	0.251	0.338	0.317	0.333
	(b) Diluted					

Ram 83

See accompanying note to the financial results

PART II

	Particulars	For the Quarter ended March 31, 2014	For the Quarter ended December 31, 2013	For the Quarter ended March 31, 2013	Audited For The Year Ended March 31, 2014	Audited For The Year Ended March 31, 2013
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	- Number of shares	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **					
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non - encumbered					
	- Number of shares	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82

	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	Nil

Notes

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 30th May 2014
2. The Company has been engaged in Pharmaceutical, chemicals and Plastic business accordingly separate segment under Accounting Standard -AS 17 reported.
3. Figures pertaining to previous periods have been regrouped and rearranged wherever necessary.

Date : 30.05.2014
Place : Indore



RAMESH SHAH
MANAGING DIRECTOR

BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2014
CIN NO. L24233MP1985PLC002709

(In Rs.)

Standalone / Consolidated Statement of Assets and Liabilities		standlone	
		31, March 2014	31, March 2013
Particulars		Audited	Audited
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	-84108795	-89113314
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	78629205	73624686
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	28705158	27945486
	(b) Trade payables	36357692	31071338
	(c) Other current liabilities	-	39071
	(d) Short-term provisions	2294621	2253234
	Sub-total Current liabilities	67357471	61309129
	TOTAL - EQUITY AND LIABILITIES	145986676	134933815
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assests	91732634	91712022
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	91732634	91712022
2	Current assets		
	Current investments		
	Inventories	2735670	3223725
	Trade receivables	41041109	33371194
	Cash and cash equivalents	1792975	1327114
	Short-term loans and advances	6153148	3905909
	Other current assets	2531139	1393851
	Sub-total - Current assets	54254042	43221793
	TOTAL - ASSETS	145986676	134933815

DATE : Date : 30.05.2014
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS



RAMESH SHAH
MANAGING DIRECTOR

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results an Capital Employed for year ended 31st March 2014 (Under Clause 41 Listing Agreement)

S.No.	Segment Revenue	Quarter Ended			Year Ended	
		March 31 ,	December 31,	March 31 ,	31 March	31 March
		2014	2013	2013	2014	2013
		Audited	Reviewed	Audited	Audited	Audited
1	Segment Revenue					
	Pharma Unit	210.69	298.78	242.33	545.97	403.67
	Chemicals Division	62.99	26.75	65.64	144.65	147.30
	Plastic Division	0.54	(12.74)	21.49	26.54	50.11
	Other	3.34	1.05	2.97	6.49	6.12
	Gross Turnover	277.57	313.84	332.43	723.66	607.21
2	Segment Results					
	Pharma Unit	83.75	(14.73)	91.40	158.29	104.99
	Chemicals Division	(78.94)	(18.71)	(17.51)	(72.58)	(7.40)
	Plastic Division	(29.94)	0.00	(4.77)	(7.52)	(9.36)
	Other	0.07	1.05	(2.24)	1.12	(2.24)
	Total Segment Profit Before Tax	(25.06)	(32.38)	66.88	79.31	85.99
	Interest Income	0.43	-	0.08	0.43	0.08
	Interest Expenses	3.82	2.45	12.00	15.07	19.05
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	(28.45)	(34.83)	54.96	64.67	67.01
	Provision for current tax	12.32	-	12.77	12.32	12.77
	Item Related Earlier Year				1.00	
	Profit After Tax	(40.77)	(34.83)	42.19	51.35	54.24
3	Capital Employed					
	(Segment Assets- Segment Liabilities)					
	Pharma Unit	137.25	163.62	(71.87)	137.25	(71.87)
	Chemicals Division	689.52	582.15	661.18	689.52	661.18
	Plastic Division	(52.88)	(23.18)	75.31	(52.88)	75.31
	Other	-	-	84.40	-	84.40
	Total Capital Employed	773.90	722.60	749.02	773.90	749.02

DATE : 30-05-2014
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.


RAMESH SHAH
MANAGING DIRECTOR